Roche Columvi gets European Commission nod as bispecific antibody for diffuse large B-cell lymphoma after initial therapy Ruchika Sharma14 April 2025 12:30 PM ISTBasel: Roche has announced that the company has received approval from the European Commission for Columvi (glofitamab) in...
USFDA accepts application for Roche Columvi combination for relapsed or refractory diffuse large B cell lymphoma Ruchika Sharma5 Dec 2024 11:30 AM ISTBasel: Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License...
Roche gets European Commission nod for fixed duration Columvi for diffuse large B-cell lymphoma Ruchika Sharma11 July 2023 4:30 PM ISTColumvi is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells.
Roche blood cancer drug Columvi gets EMA panel recommendation for EU approval Ruchika Sharma28 April 2023 5:26 PM ISTBasel: Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of...
Roche gets USFDA priority review for Glofitamab to treat relapsed or refractory large B-cell lymphoma Ruchika Sharma7 Jan 2023 2:30 PM ISTGlofitamab is an investigational CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface...
